[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1048442B - 含佐米曲坦的藥物配製劑 - Google Patents

含佐米曲坦的藥物配製劑

Info

Publication number
HK1048442B
HK1048442B HK03100515.3A HK03100515A HK1048442B HK 1048442 B HK1048442 B HK 1048442B HK 03100515 A HK03100515 A HK 03100515A HK 1048442 B HK1048442 B HK 1048442B
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulations
formulations containing
zolmitriptan
containing zolmitriptan
formulation
Prior art date
Application number
HK03100515.3A
Other languages
English (en)
Other versions
HK1048442A1 (en
Inventor
Roy Dearn Alan
Louise Williamson Sarah
John Summers Simon
John Coomer Trevor
Original Assignee
阿斯特拉曾尼卡有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1048442(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 阿斯特拉曾尼卡有限公司 filed Critical 阿斯特拉曾尼卡有限公司
Publication of HK1048442A1 publication Critical patent/HK1048442A1/xx
Publication of HK1048442B publication Critical patent/HK1048442B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK03100515.3A 1999-12-03 2003-01-21 含佐米曲坦的藥物配製劑 HK1048442B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (2)

Publication Number Publication Date
HK1048442A1 HK1048442A1 (en) 2003-04-04
HK1048442B true HK1048442B (zh) 2005-05-13

Family

ID=10865629

Family Applications (3)

Application Number Title Priority Date Filing Date
HK03100515.3A HK1048442B (zh) 1999-12-03 2003-01-21 含佐米曲坦的藥物配製劑
HK03100621.4A HK1048445B (zh) 1999-12-03 2003-01-23 含佐米曲坦的藥物配製劑
HK03105852A HK1053430A1 (en) 1999-12-03 2003-08-14 Pharmaceutical formulations containing zolmitriptan

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK03100621.4A HK1048445B (zh) 1999-12-03 2003-01-23 含佐米曲坦的藥物配製劑
HK03105852A HK1053430A1 (en) 1999-12-03 2003-08-14 Pharmaceutical formulations containing zolmitriptan

Country Status (28)

Country Link
US (2) US6750237B1 (zh)
EP (1) EP1237551B1 (zh)
JP (1) JP2003515559A (zh)
KR (1) KR100670092B1 (zh)
CN (1) CN1222287C (zh)
AT (1) ATE291914T1 (zh)
AU (1) AU778092B2 (zh)
BR (1) BRPI0016138B8 (zh)
CA (1) CA2392050C (zh)
CZ (1) CZ301528B6 (zh)
DE (1) DE60019162T2 (zh)
EE (1) EE05305B1 (zh)
ES (1) ES2236001T3 (zh)
GB (2) GB9928578D0 (zh)
HK (3) HK1048442B (zh)
HU (1) HU229458B1 (zh)
IL (2) IL149578A0 (zh)
IS (1) IS2135B (zh)
MX (1) MXPA02005319A (zh)
NO (1) NO322119B1 (zh)
NZ (1) NZ518862A (zh)
PL (1) PL200679B1 (zh)
PT (1) PT1237551E (zh)
RU (1) RU2255736C2 (zh)
SK (1) SK287228B6 (zh)
UA (1) UA75059C2 (zh)
WO (1) WO2001039772A1 (zh)
ZA (1) ZA200203704B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
WO2005115345A1 (en) * 2004-05-28 2005-12-08 Imaginot Pty Ltd Oral therapeutic compound delivery system
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
BRPI0715579A2 (pt) * 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
AU2011316225B2 (en) 2010-10-15 2016-05-19 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
HUE037732T2 (hu) 2012-04-18 2018-09-28 Contera Pharma Aps A mozgászavarok fejlett kezelésére alkalmas, szájon át szedhetõ gyógyszerészeti készítmény
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
EP3481385A1 (en) 2016-07-11 2019-05-15 Contera Pharma APS Pulsatile drug delivery system for treating morning akinesia
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238424A (en) * 1990-06-07 1993-12-23 Wellcome Found 3,5-substituted indole derivatives; medicaments and preparatory processes.
JP2000505090A (ja) * 1996-07-11 2000-04-25 ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ インドール選択的セロトニンアゴニストを含む包接錯体
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
DE59804534D1 (de) * 1997-02-05 2002-07-25 Jago Res Ag Muttenz Medizinische aerosolformulierungen
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
US20040214899A1 (en) 2004-10-28
NZ518862A (en) 2004-02-27
SK7532002A3 (en) 2002-12-03
CZ301528B6 (cs) 2010-04-07
NO20022525D0 (no) 2002-05-28
EP1237551B1 (en) 2005-03-30
HUP0203597A3 (en) 2005-07-28
HK1048442A1 (en) 2003-04-04
ATE291914T1 (de) 2005-04-15
IL149578A (en) 2008-04-13
IL149578A0 (en) 2002-11-10
NO322119B1 (no) 2006-08-14
KR20020058051A (ko) 2002-07-12
GB2373726A (en) 2002-10-02
MXPA02005319A (es) 2002-12-06
RU2255736C2 (ru) 2005-07-10
HU229458B1 (en) 2013-12-30
EP1237551A1 (en) 2002-09-11
BR0016138B1 (pt) 2013-09-10
HUP0203597A2 (hu) 2003-02-28
US6750237B1 (en) 2004-06-15
PT1237551E (pt) 2005-07-29
PL357597A1 (en) 2004-07-26
ZA200203704B (en) 2003-10-29
NO20022525L (no) 2002-05-28
DE60019162D1 (de) 2005-05-04
CA2392050A1 (en) 2001-06-07
DE60019162T2 (de) 2006-02-02
KR100670092B1 (ko) 2007-01-17
GB2373726B (en) 2004-10-20
HK1048445A1 (en) 2003-04-04
BR0016138A (pt) 2002-08-06
RU2002117649A (ru) 2004-01-27
AU1715701A (en) 2001-06-12
JP2003515559A (ja) 2003-05-07
IS6394A (is) 2002-05-24
GB0214845D0 (en) 2002-08-07
SK287228B6 (sk) 2010-03-08
IS2135B (is) 2006-08-15
GB9928578D0 (en) 2000-02-02
HK1048445B (zh) 2005-08-26
HK1053430A1 (en) 2003-10-24
UA75059C2 (uk) 2006-03-15
PL200679B1 (pl) 2009-01-30
CA2392050C (en) 2009-11-24
AU778092B2 (en) 2004-11-18
CN1402636A (zh) 2003-03-12
US7220767B2 (en) 2007-05-22
CN1222287C (zh) 2005-10-12
CZ20021901A3 (cs) 2002-11-13
EE05305B1 (et) 2010-06-15
WO2001039772A1 (en) 2001-06-07
ES2236001T3 (es) 2005-07-16
EE200200283A (et) 2003-06-16
BRPI0016138B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
GB2373726B (en) Pharmaceutical formulations containing zolmitriptan
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
GB0005251D0 (en) Therapeutic compounds
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
MY119403A (en) Novel compounds with analgesic effect.
MY129356A (en) Electrospun pharmaceutical compositions
HUP0301349A2 (hu) IL-11-tartalmú készítmények
HK1030885A1 (en) The use of isatin and oxindole derivatives in the preparation of a medicament for use in the treatment of mycobacterial disease
SE9802208D0 (sv) Novel compounds
HK1038508A1 (en) Dosage form comprising liquid formulation
AU2001289606A1 (en) Dry powder formulation comprising racecadotril
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
SE9802209D0 (sv) Novel compounds
SE0001916D0 (sv) Novel formulation
PL348202A1 (en) Pharmaceutically active composition and dispensing device
AP2000001950A0 (en) Paroxetine maleate.
ES2131482A1 (es) Formulacion acuosa de bambuterol.
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20201127